Nadia Iovieno, MD

Rapidity of Improvement With Intranasal Esketamine for MDD

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.

Rebecca S. Hock, Anna Feeney, Nadia Iovieno, et al

Meta-Analysis

Vortioxetine for Major Depressive Disorder

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...

Nadia Iovieno, George I. Papakostas, Anna Feeney, et al

Original Research

Ziprasidone Augmentation of Escitalopram for Cognition

July 25, 2017

Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...

Nadia Iovieno, Richard C. Shelton, Samuel R. Petrie, et al

Meta-Analysis

Monotherapy in Mood Disorders

May 25, 2016

Is one drug good enough? Read this review of 215 double-blind, randomized, placebo-controlled trials to discover which monotherapies have overall short-term efficacy in treating MDD and bipolar depression.

George I. Papakostas, Max A. Martinson, Maurizio Fava, et al

Review Article

The Nature of Placebo Response in Clinical Studies of Major Depressive Disorder

February 3, 2015

George I. Papakostas, Søren D. Østergaard, Nadia Iovieno

Original Research

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

July 15, 2013

Cristina Cusin, Nadia Iovieno, Dan V. Iosifescu, et al

Review Article

Correlation Between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Major Depressive Disorder: A Meta-Analysis

October 15, 2012

Nadia Iovieno, George I. Papakostas

Review Article

Does the Presence of an Open-Label Antidepressant Treatment Period Influence Study Outcome in Clinical Trials Examining Augmentation/Combination Strategies in Treatment Partial Responders/Nonresponders With Major Depressive Disorder?

April 3, 2012

Nadia Iovieno, George I. Papakostas

Article

Efficacy of Antidepressants for Late-Life Depression: A Meta-Analysis and Meta-Regression of Placebo-Controlled Randomized Trials

December 15, 2011

Enrico Tedeschini, Yeciel Levkovitz, Nadia Iovieno, et al

ASCP Corner

Assessing the Adequacy of Past Antidepressant Trials: A Clinician's Guide to the Antidepressant Treatment Response Questionnaire

August 15, 2011

Martin Desseilles, Janet Witte, Trina E. Chang, et al

Article

Antidepressants for Major Depressive Disorder and Dysthymic Disorder in Patients With Comorbid Alcohol Use Disorders: A Meta-Analysis of Placebo-Controlled Randomized Trials

April 19, 2011

Nadia Iovieno, Enrico Tedeschini, Kate H. Bentley, et al

Rapidity of Improvement With Intranasal Esketamine for MDD

Vortioxetine for Major Depressive Disorder

Ziprasidone Augmentation of Escitalopram for Cognition

Monotherapy in Mood Disorders

The Nature of Placebo Response in Clinical Studies of Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

Correlation Between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Major Depressive Disorder: A Meta-Analysis

Does the Presence of an Open-Label Antidepressant Treatment Period Influence Study Outcome in Clinical Trials Examining Augmentation/Combination Strategies in Treatment Partial Responders/Nonresponders With Major Depressive Disorder?

Efficacy of Antidepressants for Late-Life Depression: A Meta-Analysis and Meta-Regression of Placebo-Controlled Randomized Trials

Assessing the Adequacy of Past Antidepressant Trials: A Clinician's Guide to the Antidepressant Treatment Response Questionnaire

Antidepressants for Major Depressive Disorder and Dysthymic Disorder in Patients With Comorbid Alcohol Use Disorders: A Meta-Analysis of Placebo-Controlled Randomized Trials

ELSEWHERE:

FOLLOW US:

Nadia Iovieno, MD

Rapidity of Improvement With Intranasal Esketamine for MDD

Vortioxetine for Major Depressive Disorder

Ziprasidone Augmentation of Escitalopram for Cognition

Monotherapy in Mood Disorders

The Nature of Placebo Response in Clinical Studies of Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

Correlation Between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Major Depressive Disorder: A Meta-Analysis

Does the Presence of an Open-Label Antidepressant Treatment Period Influence Study Outcome in Clinical Trials Examining Augmentation/Combination Strategies in Treatment Partial Responders/Nonresponders With Major Depressive Disorder?

Efficacy of Antidepressants for Late-Life Depression: A Meta-Analysis and Meta-Regression of Placebo-Controlled Randomized Trials

Assessing the Adequacy of Past Antidepressant Trials: A Clinician's Guide to the Antidepressant Treatment Response Questionnaire

Antidepressants for Major Depressive Disorder and Dysthymic Disorder in Patients With Comorbid Alcohol Use Disorders: A Meta-Analysis of Placebo-Controlled Randomized Trials

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles